What is the efficacy of rifaximin (Xifaxan) in reducing the risk of recurrent hepatic encephalopathy (HE)?

Updated: Apr 04, 2019
  • Author: David C Wolf, MD, FACP, FACG, AGAF, FAASLD; Chief Editor: BS Anand, MD  more...
  • Print
Answer

Answer

Bass et al evaluated rifaximin’s ability to reduce the risk of recurrent hepatic encephalopathy (HE). [55] In this double-blind, placebo-controlled, multinational, phase 3 clinical trial, 299 patients received either rifaximin 550 mg or placebo BID. Each group also received lactulose. Breakthrough episodes of HE occurred in 22% of patients treated with rifaximin and 46% of patients with placebo (P< 0.001). HE-related hospitalization occurred in 14% of patients treated with rifaximin and 23% of patients treated with placebo (P = 0.01).


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!